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Abstract: Osteoporosis is a growing problem worldwide, linked to an increasingly aging 
population. Despite the availability of a wide variety of treatments for osteoporosis, a significant 
number of patients are either not being prescribed treatment or discontinue therapy as early 
as 6 months after initiation. The reasons for a lack of adherence are many but poor adherence 
increases the risk of fracture and, therefore, the disease burden to the patient and society. Results 
from large-scale, randomized clinical studies have shown that different osteoporosis treatments 
are efficacious in reducing the risk of fracture. Studies assessing the effects of discontinuing 
osteoporosis therapies show that some treatments appear to continue to protect patients from 
the risk of future fracture even when treatment is stopped. However, these trials involve patients 
who have been compliant with treatment for between 2 and 5 years, a situation not reflective of 
real-world clinical practice. In reality, patients who discontinue therapy within the first 6 months 
may never achieve the optimum protection from fracture regardless of which treatment they 
have been prescribed. Clinicians need to develop management strategies to enable patients to 
adhere to their treatment. This will ultimately result in better prevention of fracture and a lower 
burden of disease to society and patients.
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Introduction
Osteoporosis is a growing problem worldwide, linked to an aging population.1 
  Currently, a number of options are available for the treatment of postmenopausal 
osteoporosis (PMO). These include oral and intravenous (IV) bisphosphonates, hor-
mone replacement therapy (HRT), selective estrogen receptor modulators (SERMs), 
human parathyroid hormone (PTH) preparations, strontium ranelate, and denosumab, 
an inhibitor of RANKL (Receptor Activator of Nuclear Factor κB Ligand).
Despite the availability of a number of efficacious treatments for osteoporosis, the 
issues of how to achieve effective protection from future fracture are more complex than 
the availability of such treatments. Barriers to achieving maximum fracture protection 
include diagnosis, appropriate follow-up after fracture, and adherence of patients to 
prescribed treatments. Ultimately, patients who do not receive or adhere to treatment 
will be at risk for future fracture, something that carries a significant cost to the patient 
in terms of their quality of life, increased morbidity and even mortality following some 
fragility fractures.2 Nonadherence to treatment also increases a patient’s utilization of 
healthcare resources, thereby incurring a financial cost to both patient and healthcare 
provider. Understanding the factors which contribute to treatment effectiveness in clini-
cal practice is, therefore, essential in order to minimize the disease burden. The aim of Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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this review is to examine some of the barriers to diagnosis 
and patient adherence and to discuss the results from studies 
examining the consequences of discontinuing treatment.
Barriers to treatment
Lack of diagnosis
A significant barrier to achieving optimum fracture protec-
tion for an individual patient is the lack of a diagnosis of 
osteoporosis. Osteoporosis is often termed a ‘silent disease’ 
due to the lack of symptoms patients experience prior to the 
occurrence of a fracture. The presentation of a low-impact 
fracture should be a trigger to clinicians to assess fracture 
risk. However, a number of studies have indicated that this 
does not always happen. In a retrospective cohort study, 
1162 women 55 years of age or older who had a distal radial 
fracture were identified from a claims database that includes 
more than 3 million patients in the USA, enrolled in multiple 
health plans. Of these women, only 33 (2.8%) underwent a 
bone-density scan and 266 (22.9%) were treated with at least 
one approved medication for the treatment of osteoporosis. 
This means that 67% of women in this study were not even 
assessed for their risk of fracturing. Overall, only 279 (24.0%) 
of the women who sustained a distal radial fracture underwent 
either diagnostic evaluation or treatment of osteoporosis.3 The 
rate of diagnosis among men with a fragility fracture is even 
lower than for women. In a study of community-dwelling men 
aged 50 years and older, only 10.3% of men with a fragility 
fracture reported a diagnosis of osteoporosis within 5 years of 
the fracture event and less than 10% were receiving treatment.4 
These data highlight a clear diagnostic and treatment care gap 
for patients with osteoporosis.
Physician perception and recognition  
of osteoporosis
Examination of how physicians view osteoporosis might pro-
vide some indication of why patients are not diagnosed and 
treated following a fracture. Orthopedic surgeons are often 
the first clinicians to see a patient with a fragility fracture 
and as such may be best placed to make an assessment of 
whether a patient has osteoporosis and requires treatment. 
A study of the attitudes of 107 orthopedic surgeons in the 
USA showed that 68% thought that the orthopedic surgeon 
should expand their practice to include the prescribing of 
pharmacological treatment for osteoporosis. Up to 70% of the 
respondents said they would favor a program in which they 
initiated medical treatment and/or full assessment of patients 
with an apparent osteoporotic fracture, provided that a primary 
care physician assumed the continuation of pharmacological 
management and the assessment of secondary causes of 
osteoporosis. Despite this, only 52% of respondents stated 
that they routinely notify the patient’s primary care physician 
after seeing a patient with a probable osteoporotic fracture. 
This indicates that for some surgeons there is discordance 
between how they view their role in the identification of 
patients with osteoporosis and how they follow-up with pri-
mary care physicians. Most of the surgeons who responded 
to the survey (94%) were concerned about the adverse events 
(AEs) associated with treatments for osteoporosis and 47% 
were concerned enough about AEs that they would rather 
avoid prescribing them altogether.5 The study did not examine 
whether there were specific AEs that prevented surgeons from 
wanting to prescribe osteoporosis treatments. This perception 
by clinicians regarding the safety of treatments for osteoporo-
sis represents another potential barrier to treatment.
Within primary care, recognition of osteoporosis by phy-
sicians has proven to be low. For example, in a large survey of 
more than 85,000 Australian women aged 60 years and older 
who visited a primary care physician, approximately 57,000 
reported symptoms and/or risk factors for   osteoporosis. Of 
the 85,000 women who took part in the survey, 29% reported 
fractures. Despite this, only 8% of the women reporting 
symptoms and or/risk factors for osteoporosis had undergone 
bone mineral density (BMD) testing and only 25% of women 
reported a diagnosis of osteoporosis.6
Rates of treatment with  
osteoporosis therapies
Although there is still a gap in care between the number of 
patients who require treatment and the number who receive 
it, treatment with osteoporosis therapies was shown to have 
increased from 7% to 31% between 1995 and 2004, in patients 
who had experienced a hip fracture.7 During this period a num-
ber of bisphosphonates such as alendronate and risedronate were 
approved for use in the treatment of osteoporosis. Although the 
rates of prescribing of osteoporosis medications have increased 
over time,8 there is evidence that prescribing of bisphosphonates 
is currently not increasing or is even on the decline.
The problem of noncompliance, 
nonpersistence and treatment 
discontinuation
Compliance and persistence with 
osteoporosis treatments
A lack of adherence (compliance and persistence) by 
patients to their treatment is an issue for most chronic Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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diseases,   including osteoporosis. Evidence for the efficacy 
of osteoporosis treatments comes from randomized, 
controlled clinical trials (RCTs) in which patients are care-
fully monitored and are in regular contact with healthcare 
professionals.9–16 This results in compliance and persistence 
rates of between 60% and 81%.11,16–18 However, in the real-
world clinical practice setting, numerous studies have shown 
that compliance and persistence by patients to osteoporosis 
treatment is poor.19–26
Data from a study by Siris et al of more than 35,000 
women who received a bisphosphonate prescription showed 
that 57% of those prescribed alendronate or risedronate 
(daily or weekly doses) were noncompliant and 80% were 
nonpersistent within 2 years of initiating treatment.25 In 
this study, compliance was defined using the medication 
possession ratio (MPR), calculated as the sum of the days’ 
supply divided by the follow-up time. Patients were deemed 
compliant if their MPR was $0.80. Persistence was defined 
as the length of time a patient received continuous therapy 
without a gap in refills .30 days. The study showed that 
noncompliance or nonpersistence with treatment led 
to a significant reduction in treatment benefit such that 
patients who only took half their medication over 2 years 
achieved no better efficacy than if they had never taken 
any medication.25 Another study by Downey et al used 
a managed care administration claims database from the 
USA to examine the adherence and persistence of 10,566 
women, newly diagnosed with PMO to treatment with 
alendronate, risedronate or raloxifene.20 Adherence rates 
to treatment with both daily and weekly alendronate and 
risedronate were 60.7%, and 58.4% respectively, and with 
raloxifene were 53.9%. Persistence rates at 12 months were 
21.3% for alendronate, 19.4% for risedronate and 16.2% 
for raloxifene. The study showed that persistence rapidly 
declined in the first 3 months of treatment, with a slower, 
more gradual decline over the following 9 months. The 
lack of persistence at 12 months was comparable in this 
study to that found by Siris et al at 2 years.25 A recent meta-
analysis of 15 studies assessing adherence to osteoporosis 
treatment showed that the mean number of days patients 
persisted with alendronate, risedronate or ibandronate treat-
ment (n = 236,540) was 184 (95% CI 164–204). The mean 
MPR for patients treated with alendronate or risedronate 
(n = 234,737) was 66.9% (95% CI 63–70).27 The results 
from this meta-analysis show that across multiple studies, 
patients are discontinuing their treatment within 6 months 
and that, even within this timeframe, they are not taking 
their medication on a regular basis.
A lack of persistence to treatment by a patient may also 
not be permanent or irreversible. A study of Australian vet-
erans who were prescribed oral bisphosphonates following 
a fracture showed that although the majority of users (68%) 
did not persist with treatment, 19% of users had two treat-
ment episodes and 13% had three or more episodes of use. 
In this study an episode of use was determined as the number 
of treatment days between the first prescription and the date 
of the last prescription plus 35 days.28 These data indicate 
that there may be opportunities for clinicians to restart their 
patients on treatment even when they have previously stopped 
taking it and that finding out the root causes of why a patient 
has desisted are important in increasing the length of time 
on treatment.
In addition, clinicians may also have a misconcep-
tion of how adherent their patients are. In a survey of 412 
clinicians, it was estimated that 69.2% of patients were 
adherent after 12 months of treatment. Pharmacy claims for 
the same patients showed that only 48.7% were adherent 
after 12 months. Clinicians’ perceptions did not signifi-
cantly differ according to medication class or frequency of 
administration.29
Reasons for lack of compliance and  
persistence with osteoporosis therapies
Determining why patients are noncompliant and nonper-
sistent is important in enabling clinicians to select the most 
appropriate treatment. Numerous studies have examined 
the reasons why patients fail to comply with instructions on 
how to take their medication or stop taking their medica-
tion altogether. Common reasons for nonadherence include 
AEs, either real or perceived, complicated dosing regimens 
and a lack of knowledge surrounding osteoporosis and the 
importance of fracture prevention.30 AEs are an issue for 
all osteoporosis treatments, but events such as GI irritation, 
which may be associated with oral bisphosphonates, can often 
be made worse if patients do not take their medication accord-
ing to the instructions (sufficient water, upright position 
and fasting state).31 Other reasons for a lack of adherence to 
treatment include the dosing intervals of different treatments. 
Studies which have examined the adherence of patients have 
shown that patients prefer and are more adherent to weekly 
versus daily alendronate32,33 and monthly versus weekly 
bisphosphonates.34 However, even with weekly treatment, 
patients still had suboptimal adherence.35 The availability 
of intravenous (IV) bisphosphonates such as ibandronate 
(quarterly dosing) and zoledronic acid (annual dosing) may 
lead to improved adherence by patients. A preference study Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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of patients recently diagnosed with osteoporosis showed that 
out of oral bisphosphonates (daily or weekly), IV bisphos-
phonates every 3 months, or IV bisphosphonates once-yearly, 
65% of patients preferred annual over weekly dosing.36
Adherence may also be influenced by the use of 
generic versions of branded medication. A recent study by 
Ringe and Moller of the differences in patient persistence 
between generic and original branded once-weekly bispho-
sphonates, using the clinical records of 204 women, showed 
clear differences in the persistence rates between generic 
and branded oral bisphosphonates.33 At 12 months, 68% of 
patients were still taking generic alendronate compared with 
84% of patients taking branded alendronate (Fosamax®). The 
persistence rates for this study are much higher than has 
been seen in other clinical practice studies;19,20,25 however, 
it does suggest that patients are less likely to persist with 
generic alendronate compared with branded. Examination of 
the number of GI AEs experienced by patients in this study 
showed that significantly more patients taking generic alen-
dronate experienced a GI AE than patients taking branded 
alendronate (32 patients versus 15 patients, respectively; 
P , 0.05).33 These data are further supported by a report 
showing that patients who were previously stable on doses of 
branded alendronate experienced an increase in AEs which 
resulted in treatment discontinuation after switching to a 
generic version of alendronate.37
Belief in the importance of taking medication for the 
treatment of osteoporosis and the relationship between the 
patient and healthcare provider are two important consid-
erations when trying to achieve maximum adherence.30 
Patients must understand the nature of the disease and how 
it progresses in order to compensate for the asymptomatic 
nature of osteoporosis. A close relationship between the 
healthcare provider and the patient has been shown to 
improve adherence by 57% among postmenopausal women 
with osteopenia.38
Consequences of a lack of compliance  
and persistence with osteoporosis  
therapies
A lack of adherence to osteoporosis treatment will ulti-
mately have an effect on the degree of fracture protection 
patients might achieve. In a study of over 38,000 women 
with PMO who received a prescription for a bisphospho-
nate, low compliance (MPR , 80%) was found to be 
associated with a 31% higher risk of fracture (P , 0.0001). 
Hospitalization rates were 47% higher in patients with 
poor compliance (MPR , 50%) than in those patients 
with excellent compliance (MPR . 90%).22 In a later 
study by Penning-van Beest et al of 8,822 female bispho-
sphonate users, a MPR of ,20% was associated with an 
80% increased fracture risk compared with patients with 
a MPR of $90%.39 Results from a meta-analysis of adher-
ence to osteoporosis treatments by Danese et al showed 
that the risk of fracture was 46% greater for patients with 
poor compliance to bisphosphonates (MPR , 80%) com-
pared with highly compliant patients (MPR $ 80%), over 
1–2.5 years. Examination of the fracture risk for different 
fracture sites showed that lack of compliance affected the 
risk of clinical vertebral fractures most (43%), followed 
by hip (28%) and nonvertebral fractures (16%).40 These 
findings have clear implications for wasted healthcare 
expenditures on unused medication, and increased out-
lays for hospital and other direct and indirect medical 
costs. Danese et al have modeled the effect of adherence 
on lifetime fractures in osteoporotic women who receive 
treatment with oral bisphosphonates.40 They compared the 
benefits of patients being highly compliant with treatment, 
both in terms of fracture rates and monetary cost, with the 
current state of adherence with daily and weekly bispho-
sphonate therapies in the USA. Optimal adherence was 
defined as a MPR . 90%. Using this model, the overall 
fracture rates per 1000 patient years for usual adherence 
were calculated to be 58 (95% CI 51–64) compared with 
44 (95% CI 36–53) for optimal adherence. The increase 
in fracture costs between usual and optimal adherence was 
estimated to be USD $2100 (95% CI 400–7300) based on 
site-specific United States Department of Labor Consumer 
Price Index-based estimates for the 1-year direct medical 
cost of fracture. Despite the increase in fracture costs 
between usual and optimum adherence, the study showed 
that optimal adherence was more expensive overall, com-
pared with usual adherence (USD $1700 [95% CI 4100 
to -3300]). When this was examined further, the authors 
calculated that the increase in cost was due to the cost of 
medication (generic and branded). In this study, a number 
of assumptions were made in the process of assessing cost. 
For example, patients were assumed to be free of fracture 
at the time treatment was initiated and the cost of fracture 
after 1 year and the quality of life decrements associated 
with fracture were not incorporated. The authors also 
assumed that all patients with a T score #-2.5 were treated 
with bisphosphonates. It is clear that in clinical practice not 
all of these assumptions will be true, and so the estimates 
of the cost of adherence, both usual and optimum, should 
be interpreted with caution.40Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Consequences of discontinuing  
osteoporosis treatment
The efficacy of different osteoporosis treatments has been dem-
onstrated in a number of large-scale clinical trials (Tables 1–4). 
Follow-up studies have examined the clinical consequences of 
discontinuing treatment, information that is important given 
the previously discussed issues of poor persistence.
HRT and SeRMs
In a study of older women aged 65–77 years who received 3 
years of treatment with estrogen or placebo and 2 years of no 
further treatment, overall spine BMD was not significantly 
different to baseline at the end of 5 years. The lack of overall 
difference in BMD was the result of a loss of BMD during 
the 2 years of no treatment that counteracted the gains made 
during active treatment.41 The fall in BMD after discontinu-
ation of estrogen was also accompanied by a rapid increase 
(rebound) back to baseline in the bone turnover marker (BTM) 
urinary crosslinked N-telopeptide of type I collagen (urinary 
NTX), indicating a significant increase in bone remodeling in 
this population of women.41 Although this study has shown 
a rapid loss of BMD after discontinuation of treatment, a 
follow-up study (5, 11 or 15 years) of healthy postmenopausal 
women who had received 2–3 years of treatment with HRT in 
their early postmenopausal years showed that despite a loss of 
BMD once treatment was stopped, patients previously treated 
with HRT had a significantly lower risk of vertebral fracture 
at the time of follow-up compared with women on placebo 
(odds ratio 0.47 [95% CI 0.24–0.93]; P = 0.03). The risk of 
nonvertebral fractures was 32% lower in patients treated with 
HRT, compared with patients in the placebo group, but did 
not reach statistical significance.42
Data from a study of postmenopausal women who were 
randomized to receive treatment with raloxifene 60 mg 
or estrogen for 5 years showed that despite significant 
increases in lumbar spine BMD versus baseline (P = 0.024 
and P = 0.045, respectively), within 1 year of discontinua-
tion of treatment lumbar spine BMD was significantly lower 
compared with the end-of-treatment values (P = 0.001 and 
P = 0.012, respectively) (Figure 1A). A significant decline in 
femoral neck BMD was also observed after discontinuation 
of raloxifene treatment (Figure 2A).43
Bisphosphonates
Alendronate
In the FIT Long-term Extension (FLEX) follow-up study 
women who had received treatment with alendronate for 
5 years during the FIT trial were re-randomized to receive 
alendronate 5 or 10 mg/day or placebo for a further 5 years.44 
Women randomized to placebo, and who therefore discontin-
ued treatment with alendronate, showed a moderate decline 
in BMD at the total hip (-3.38%), femoral neck (-1.48%) 
(Figure 2B) and trochanter (-3.25%) at the end of 5 years of 
placebo treatment, compared with the end of treatment with 
alendronate. In contrast, lumbar spine BMD increased for the 
same women during this period (Figure 1B). Mean levels of 
BTMs gradually increased in women who discontinued treat-
ment with alendronate compared with women who continued 
taking alendronate. However, when compared with pretreat-
ment levels in the FIT study 10 years previously, levels of 
serum C-telopeptide of type I collagen (CTX) (Figure 3A) 
and bone alkaline phosphatase (ALP) at the end of 5 years of 
placebo treatment had not returned to baseline pretreatment 
levels.44 Despite the changes in BMD and BTMs there were 
no significant differences in RR of all clinical fractures or 
nonvertebral fractures between women who continued with 
alendronate treatment and those who received placebo treat-
ment over the 5-year follow-up. A significant difference in 
risk of clinical vertebral fractures was observed, with a RR 
of a clinical vertebral fracture of 0.45 (95% CI 0.24–0.85) 
for women who continued with alendronate treatment versus 
those who switched to placebo. A post-hoc analysis of the 
data showed that in women who did not have a vertebral 
fracture at FLEX baseline, continuation of treatment with 
alendronate reduced nonvertebral fractures in women with 
FLEX baseline femoral neck T-scores ,-2.5 (RR 0.50; 95% 
CI 0.26–0.96) but not with T-scores .-2.5 and ,-2 (RR 
0.79; 95% CI 0.37–1.66) or with T-scores .-2 (RR 1.41; 
95% CI 0.75–2.66) (p for interaction = 0.019). In the group 
of women with a vertebral fracture at baseline, there were 
no significant interactions between FLEX baseline femoral 
neck BMD and the effect of continued treatment with alen-
dronate on any fracture outcomes, although the numbers of 
women who experienced a fracture were small.45 In patients 
who received placebo, neither prevalent vertebral fracture at 
baseline or femoral neck T-score had a significant interaction 
on the risk of nonvertebral or clinical vertebral fractures. 
However, data from this group were not analyzed using both 
parameters together.44 It should perhaps be noted that in this 
study, only 72% of patients were still taking their assigned 
medication at the end of the 5-year study.44
Risedronate
Follow-up assessment of 599 women with PMO who took 
part in the Vertebral Efficacy with Risedronate Therapy trials 
showed that 1 year after stopping treatment, lumbar spine Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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BMD had significantly decreased compared with placebo 
at the end of 3 years of treatment (Figure 1C). However, the 
decline was gradual and BMD remained significantly above 
baseline levels and above the lumbar spine BMD of the original 
placebo group. A significant decline in femoral neck BMD 
also occurred in the year after treatment was discontinued 
(Figure 2C). Levels of urinary NTX and bone ALP gradually 
rose following discontinuation, as with treatment with alen-
dronate, levels did not return to baseline within the follow-up 
period (Figure 3B). Despite gradual but significant declines in 
BMD, there remained a significant reduction in risk of verte-
bral fractures in the former risedronate group compared with 
the placebo group, 1 year after treatment was stopped.46
ibandronate
There is currently a lack of published information regarding 
the clinical consequences of discontinuing treatment with 
ibandronate.
Zoledronic acid
Devogelaer et al showed that in a Phase II, dose-ranging study 
of treatment with zoledronic acid 4 mg over 5 years, women 
with PMO who received 3 years of treatment and were then 
followed up for 2 years showed an overall gain in BMD at the 
end of treatment which was maintained during the years with-
out treatment.47 Lumbar spine BMD at 5 years had increased 
by 9.01% compared with baseline, proximal femur by 4.92%, 
distal radius by 2.60% and total body by 3.59%. Analysis of 
serum levels of CTX and bone ALP show that once treatment 
had been stopped, levels of both markers gradually rose but 
did not return to baseline during the follow-up period. Levels 
were also well within the normal range for the duration of 
the study and follow-up.47 Data from a 3-year extension to 
the HORIZON-PFT are expected shortly and should provide 
information about the effects of continuing versus discontinu-
ing treatment with zoledronic acid.
RANKL inhibitors
Denosumab
Data on the effects of discontinuing treatment with denosumab 
are limited; however, in a Phase III trial, 332 postmenopausal 
women with low bone mass who received treatment with 
either denosumab 60 mg or placebo every 6 months for 2 
years showed a rapid decrease in lumbar spine and total hip 
BMD back to baseline within 12 months of discontinuing 
treatment. Total hip BMD continued to decrease over the 
next 12 months.48 Data on changes in BTMs for this study 
are currently unavailable. However, in a phase II study, Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 2 Summary of results from trials of antiresorptive osteoporosis treatments
Study Treatments Fracture reduction versus placebo  
over 3 years (RR [95% CI])
Mean change from baseline over 3 years (percentage)
Vertebral Nonvertebral Hip Lumbar spine BMD Femoral neck BMD Serum CTX Serum bone ALP
Postmenopausal estrogen/Progestin 
interventions (PePi)18
Placebo
Conjugated equine estrogen (Cee)  
0.625 mg/day
Cee 0.625 mg/day and  
medroxyprogesterone acetate  
(MPA) 10 mg/day (days 1–12) 
Cee 0.625 mg/day and MPA 2.5 mg/day 
Cee 0.625 mg/day and micronised  
progesterone 200 mg/day (days 1–12)
 
N/R
 
N/R
 
N/R
–2.8%
All active  
treatments = 5.1%
N/R N/R
N/R
N/R
N/R
Multiple Outcomes of Raloxifene  
evaluation (MORe)9
Placebo
 
Raloxifene 60 mg/day
 
 
Raloxifene 120 mg/day
 
 
0.7 (0.5–0.8)
 
 
0.5 (0.4–0.7)
 
 
Raloxifene combined   
group = 0.9 (0.8–1.1)
 
N/R
 
 
N/R
 
 
N/R
N/R
 
Change versus placebo 
2.1%, P , 0.001
 
Change from placebo 
2.7%, P , 0.001
N/R
 
Change versus placebo 
2.65, P , 0.001
 
Change from placebo 
2.7%, P , 0.001
Urinary CTX 
-8.1%
Urinary CTX 
-34.0%, P , 0.001  
versus placebo
Urinary CTX 
-31.5%, P , 0.001 
versus placebo
N/R
 
N/R
 
 
N/R
Fracture intervention Trial (FiT)10  
Combined population
Placebo
Alendronate 5 mg/day (for 2 years) then 10 mg/day 
(for 1 year)
 
0.52  (0.42–0.66), P , 0.001
 
0.73 (0.61–0.87),  
P , 0.001
 
0.47 (0.26–0.79), P = 0.005
N/R
N/R
N/R
N/R
N/R
N/R
N/R
N/R
Clinical  
fracture arm67
Placebo
Alendronate 5 mg/day (for 2 years) then 10 mg/day 
(for 2 years)a
 
0.56 (0.39–0.80)
 
0.88 (0.74–1.04)
 
0.79 (0.43–1.44)
1.5%
8.3%, P , 0.001 versus placebo
–0.8%
3.8%, P , 0.001 versus placebo
N/R
N/R
N/R
N/R
vertebral  
fracture arm68
Placebo
Alendronate 5 mg/day (for 2 years) then 10 mg/day 
(for 1 year)
 
0.45 (0.27–0.72)
 
0.80 (0.63–1.01)
 
0.49 (0.23–0.99)
 
Change versus placebo 
6.2%, P , 0.001 versus placebo
 
Change versus placebo 
4.1%, P , 0.001 versus placebo
N/R
N/R
N/R
N/R
Alendronate Phase iii  
Osteoporosis Studies63
Placebo
Alendronate 5 mg/day
 
Alendronate 10 mg/day
 
Alendronate 20 mg/day (for 2 years then switched 
to 5 mg/day)
 
Pooled alendronate data = 0.52 
(0.28–0.95)
N/R
 
N/R
 
P = NS
 
N/R
 
N/R
 
N/R
 
N/R
 
N/R
∼–0.8%†
∼5.0, P = NS versus placebo†
 
∼8.2%, P , 0.001 versus placebo†
 
∼7.8%, P = NS versus placebo†
∼-1.2%†
∼1.7, P = NS versus placebo†
 
∼3.2%, P , 0.001 versus placebo†
 
∼4.7%, P = NS versus placebo†
N/R
N/R
 
N/R
 
N/R
N/R
N/R
 
N/R
 
N/R
Fosamax® interventional  
Trial Study (FOSiT)b,64
Placebo
Alendronate 10 mg/day
 
N/R
 
After 1 year 
0.53 (0.30–0.90)
 
N/R
0.1%, P = NS versus baseline
5.0%, P , 0.001 versus baseline
 
 
1.1%, P , 0.05 versus baseline
-0.2, P = NS versus baseline
2.3%, P , 0.001 versus baseline 
 
 
-1.2%, P , 0.05 versus baseline
Urinary NTX -21%,
Urinary NTX -74%, 
P , 0.001versus 
placebo 
N/R
-11%
-52%, P , 0.001 
versus placebo
 
Median change -7%
Vertebral Efficacy With Risedronate  
Therapy-National (veRT-NA)13
Placebo
Risedronate 5 mg
 
0.59 (0.43–0.82), P = 0.001
 
0.60 (0.39–0.94),  
P = 0.02
 
N/R
 
5.4%, P , 0.05 versus baseline
 
1.6%, P , 0.05 versus baseline
 
N/R
 
Median change -33%
Vertebral Efficacy With Risedronate  
Therapy-Multinational (veRT-MN)69
Placebo
Risedronate 5 mg
 
0.51 (0.36–0.73), P , 0.001
 
P = NS
 
N/R
N/R
Change versus placebo 5.9% 
(95% Ci 4.5–7.3), P , 0.001
N/R
Change versus placebo 3.1% 
(95% Ci 1.8–4.5), P , 0.001)
N/R
N/R
N/R
N/R
Hip intervention Program Study66 Placebo
Risedronate 5 mg*
 
N/R
 
N/R
 
All women = 0.7 (0.6–0.9),  
P = 0.02 
women aged  
70–79 years = 0.6 (0.4–0.9),  
P = 0.009 
women aged 
$80 years = no significant  
reduction
N/R
N/R
N/R
N/R 
 
Change versus placebo 
3.4%, P , 0.001 
 
N/R
N/R
N/R
N/R
N/R
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Table 2 Summary of results from trials of antiresorptive osteoporosis treatments
Study Treatments Fracture reduction versus placebo  
over 3 years (RR [95% CI])
Mean change from baseline over 3 years (percentage)
Vertebral Nonvertebral Hip Lumbar spine BMD Femoral neck BMD Serum CTX Serum bone ALP
Postmenopausal estrogen/Progestin 
interventions (PePi)18
Placebo
Conjugated equine estrogen (Cee)  
0.625 mg/day
Cee 0.625 mg/day and  
medroxyprogesterone acetate  
(MPA) 10 mg/day (days 1–12) 
Cee 0.625 mg/day and MPA 2.5 mg/day 
Cee 0.625 mg/day and micronised  
progesterone 200 mg/day (days 1–12)
 
N/R
 
N/R
 
N/R
–2.8%
All active  
treatments = 5.1%
N/R N/R
N/R
N/R
N/R
Multiple Outcomes of Raloxifene  
evaluation (MORe)9
Placebo
 
Raloxifene 60 mg/day
 
 
Raloxifene 120 mg/day
 
 
0.7 (0.5–0.8)
 
 
0.5 (0.4–0.7)
 
 
Raloxifene combined   
group = 0.9 (0.8–1.1)
 
N/R
 
 
N/R
 
 
N/R
N/R
 
Change versus placebo 
2.1%, P , 0.001
 
Change from placebo 
2.7%, P , 0.001
N/R
 
Change versus placebo 
2.65, P , 0.001
 
Change from placebo 
2.7%, P , 0.001
Urinary CTX 
-8.1%
Urinary CTX 
-34.0%, P , 0.001  
versus placebo
Urinary CTX 
-31.5%, P , 0.001 
versus placebo
N/R
 
N/R
 
 
N/R
Fracture intervention Trial (FiT)10  
Combined population
Placebo
Alendronate 5 mg/day (for 2 years) then 10 mg/day 
(for 1 year)
 
0.52  (0.42–0.66), P , 0.001
 
0.73 (0.61–0.87),  
P , 0.001
 
0.47 (0.26–0.79), P = 0.005
N/R
N/R
N/R
N/R
N/R
N/R
N/R
N/R
Clinical  
fracture arm67
Placebo
Alendronate 5 mg/day (for 2 years) then 10 mg/day 
(for 2 years)a
 
0.56 (0.39–0.80)
 
0.88 (0.74–1.04)
 
0.79 (0.43–1.44)
1.5%
8.3%, P , 0.001 versus placebo
–0.8%
3.8%, P , 0.001 versus placebo
N/R
N/R
N/R
N/R
vertebral  
fracture arm68
Placebo
Alendronate 5 mg/day (for 2 years) then 10 mg/day 
(for 1 year)
 
0.45 (0.27–0.72)
 
0.80 (0.63–1.01)
 
0.49 (0.23–0.99)
 
Change versus placebo 
6.2%, P , 0.001 versus placebo
 
Change versus placebo 
4.1%, P , 0.001 versus placebo
N/R
N/R
N/R
N/R
Alendronate Phase iii  
Osteoporosis Studies63
Placebo
Alendronate 5 mg/day
 
Alendronate 10 mg/day
 
Alendronate 20 mg/day (for 2 years then switched 
to 5 mg/day)
 
Pooled alendronate data = 0.52 
(0.28–0.95)
N/R
 
N/R
 
P = NS
 
N/R
 
N/R
 
N/R
 
N/R
 
N/R
∼–0.8%†
∼5.0, P = NS versus placebo†
 
∼8.2%, P , 0.001 versus placebo†
 
∼7.8%, P = NS versus placebo†
∼-1.2%†
∼1.7, P = NS versus placebo†
 
∼3.2%, P , 0.001 versus placebo†
 
∼4.7%, P = NS versus placebo†
N/R
N/R
 
N/R
 
N/R
N/R
N/R
 
N/R
 
N/R
Fosamax® interventional  
Trial Study (FOSiT)b,64
Placebo
Alendronate 10 mg/day
 
N/R
 
After 1 year 
0.53 (0.30–0.90)
 
N/R
0.1%, P = NS versus baseline
5.0%, P , 0.001 versus baseline
 
 
1.1%, P , 0.05 versus baseline
-0.2, P = NS versus baseline
2.3%, P , 0.001 versus baseline 
 
 
-1.2%, P , 0.05 versus baseline
Urinary NTX -21%,
Urinary NTX -74%, 
P , 0.001versus 
placebo 
N/R
-11%
-52%, P , 0.001 
versus placebo
 
Median change -7%
Vertebral Efficacy With Risedronate  
Therapy-National (veRT-NA)13
Placebo
Risedronate 5 mg
 
0.59 (0.43–0.82), P = 0.001
 
0.60 (0.39–0.94),  
P = 0.02
 
N/R
 
5.4%, P , 0.05 versus baseline
 
1.6%, P , 0.05 versus baseline
 
N/R
 
Median change -33%
Vertebral Efficacy With Risedronate  
Therapy-Multinational (veRT-MN)69
Placebo
Risedronate 5 mg
 
0.51 (0.36–0.73), P , 0.001
 
P = NS
 
N/R
N/R
Change versus placebo 5.9% 
(95% Ci 4.5–7.3), P , 0.001
N/R
Change versus placebo 3.1% 
(95% Ci 1.8–4.5), P , 0.001)
N/R
N/R
N/R
N/R
Hip intervention Program Study66 Placebo
Risedronate 5 mg*
 
N/R
 
N/R
 
All women = 0.7 (0.6–0.9),  
P = 0.02 
women aged  
70–79 years = 0.6 (0.4–0.9),  
P = 0.009 
women aged 
$80 years = no significant  
reduction
N/R
N/R
N/R
N/R 
 
Change versus placebo 
3.4%, P , 0.001 
 
N/R
N/R
N/R
N/R
N/R
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Table 2 (Continued)
Study Treatments Fracture reduction versus placebo  
over 3 years (RR [95% CI])
Mean change from baseline over 3 years (percentage)
Vertebral Nonvertebral Hip Lumbar spine BMD Femoral neck BMD Serum CTX Serum bone ALP
ibandronate Osteoporosis vertebral  
Fracture Trial in North America and  
europe (BONe)12,70
Placebo
ibandronate 2.5 mg/day
ibandronate 20 mg every other day for 12 doses 
every 3 months
 
0.38 (41–75), P = 0.0001
0.50 (26–66), P = 0.0006
 
P = NS
P = NS
 
N/R
 
 
N/R
1.3%
6.5%
 
 
5.7%
–0.6%
2.8%
 
 
2.4%
N/R
Urinary CTX 
-65.3%, P , 0.001  
versus placebo
Urinary CTX 
-52.7%, P , 0.001  
versus placebo
N/R
N/R
 
 
N/R
Health Outcomes and Reduced 
incidence with Zoledronic Acid Once 
Yearly (HORiZON) Pivotal Fracture 
Trial11
Placebo
Zoledronic acid 5 mg once yearly
 
0.30 (0.24–0.38), P , 0.001
 
0.75 (0.64–0.87), 
P , 0.001
 
 
 
 
0.59 (0.42–0.83), P = 0.002
 
 
 
 
Change versus placebo 
6.71% (95% Ci 5.69–7.74)
 
 
 
 
Change versus placebo 
5.06% (95% Ci 4.76–5.36)
Mean value at 
36 months 
0.473 ng/mL
 
Mean value at 
36 months 
0.205 ng/mL
Mean value at 
36 months 
53.43 ng/mL
 
Mean value at 
36 months 
10.61 ng/mL
Health Outcomes and Reduced 
incidence with Zoledronic Acid Once 
Yearly (HORiZON) Recurrent 
Fracture Trial59
Placebo
Zoledronic acid 5 mg once yearly
 
0.54 (0.32–0.92), P = 0.02
 
0.73 (0.55–0.98), 
P = 0.03
 
P = NS
N/R
N/R
0.7%
3.6%, P , 0.001 versus placebo
N/R
N/R
N/R
N/R
Fracture Reduction evaluation of  
Denosumab in Osteoporosis every  
6 Months (FReeDOM)17
Placebo
Denosumab 60 mg/3 months
 
0.32 (0.26–0.41), P , 0.001
 
0.80 (0.67–0.95), 
P = 0.01
 
0.60 (0.37–0.97), P = 0.04
N/R
Change versus placebo 
9.2%, P , 0.001 versus placebo
N/R
N/R
N/R
Change versus placebo 
-72%
N/R
N/R
Spinal Osteoporosis Therapeutic  
intervention (SOTi)15
Placebo
Strontium ranelate 2 g/day
 
0.59 (0.48–0.73), P , 0.001
 
P = NS
 
N/R
N/R
Change versus placebo 
14.4%, P , 0.001 versus placebo
N/R
Change versus placebo 
8.3%, P , 0.001 versus placebo
∼520 pmol/L‡
∼290 pmol/L‡
∼1.4 ng/mL‡
∼2.35 ng/mL‡
Treatment of Peripheral 
Osteoporosis (TROPOS)c 16
Placebo
Strontium ranelate 2 g/day
 
0.61 (0.51–0.73), P , 0.001
 
0.84 (0.702–0.995), 
P = 0.04
 
P = NS
N/R
N/R
N/R
Change versus placebo 
8.2%, P , 0.001 versus placebo
N/R
N/R
N/R
N/R
Notes: All trials were 3-year, randomized, double-blind, placebo-controlled with the exception of: aMean treatment duration was 4.2 years; b1-year trial; c5-year trial; 
*Risedronate 2.5 mg and 5 mg doses were combined for analysis of efficacy; †estimated from Figure1 from Liberman UA, et al. (1995) N Engl J Med. 333:1437–1443; ‡estimated 
from Figure 4 from Meunier PJ, et al (2004). N Engl J Med. 350:459–468.
Abbreviations: CI, confidence interval; N/R, not reported; RR, risk reduction; NS, not significant; BMD, bone mineral density; CTX, serum C-telopeptide of type I collagen; 
ALP, alkaline phosphatase.
  discontinuation of denosumab 30 mg administered every 
3 months, resulted in an increase in serum CTX and bone 
ALP that went beyond baseline levels within 12 months 
 ( Figure 3C).49 There are no published data on the antifracture 
efficacy of denosumab after discontinuing treatment; however, 
due to the rapid loss of BMD and increase in BTMs observed 
thus far, data on how the risk of future fracture is affected 
once treatment is stopped is needed to determine whether 
antifracture efficacy with denosumab is long lasting.
Strontium ranelate
Strontium ranelate consists of two atoms of stable strontium 
and an organic moiety (ranelic acid) that when taken orally 
exerts modest antiresorptive and anabolic effects on bone.15 
In the SOTI trial extension, after 4 years of treatment with 
strontium ranelate, patients crossed over from active treat-
ment to placebo for a further year. During the year patients 
were taking placebo, lumbar spine BMD decreased compared 
with patients who remained on treatment who experienced 
an increase in lumbar spine BMD. BTMs also changed dur-
ing the year of treatment with placebo; within 3 months of 
moving to placebo, significant decreases in bone ALP and 
significant increases in serum CTX were observed. Despite 
changes in both lumbar spine BMD and BTMs, the differ-
ence in annual vertebral fracture incidence between patients 
who continued on active treatment and those who moved to 
placebo was nonsignificant. This was also true for the propor-
tion of patients with new nonvertebral fractures.50
Bone-forming agents
Parathyroid hormone (PTH)
Both teriparatide (PTH 1–34) and full length PTH (1–84) are 
anabolic agents for bone, which stimulate osteoblastic new 
bone formation and hence an increase in bone mass.
Teriparatide is a recombinant form of human PTH 
(1–34). In a follow-up to the Fracture Prevention Trial, Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 2 (Continued)
Study Treatments Fracture reduction versus placebo  
over 3 years (RR [95% CI])
Mean change from baseline over 3 years (percentage)
Vertebral Nonvertebral Hip Lumbar spine BMD Femoral neck BMD Serum CTX Serum bone ALP
ibandronate Osteoporosis vertebral  
Fracture Trial in North America and  
europe (BONe)12,70
Placebo
ibandronate 2.5 mg/day
ibandronate 20 mg every other day for 12 doses 
every 3 months
 
0.38 (41–75), P = 0.0001
0.50 (26–66), P = 0.0006
 
P = NS
P = NS
 
N/R
 
 
N/R
1.3%
6.5%
 
 
5.7%
–0.6%
2.8%
 
 
2.4%
N/R
Urinary CTX 
-65.3%, P , 0.001  
versus placebo
Urinary CTX 
-52.7%, P , 0.001  
versus placebo
N/R
N/R
 
 
N/R
Health Outcomes and Reduced 
incidence with Zoledronic Acid Once 
Yearly (HORiZON) Pivotal Fracture 
Trial11
Placebo
Zoledronic acid 5 mg once yearly
 
0.30 (0.24–0.38), P , 0.001
 
0.75 (0.64–0.87), 
P , 0.001
 
 
 
 
0.59 (0.42–0.83), P = 0.002
 
 
 
 
Change versus placebo 
6.71% (95% Ci 5.69–7.74)
 
 
 
 
Change versus placebo 
5.06% (95% Ci 4.76–5.36)
Mean value at 
36 months 
0.473 ng/mL
 
Mean value at 
36 months 
0.205 ng/mL
Mean value at 
36 months 
53.43 ng/mL
 
Mean value at 
36 months 
10.61 ng/mL
Health Outcomes and Reduced 
incidence with Zoledronic Acid Once 
Yearly (HORiZON) Recurrent 
Fracture Trial59
Placebo
Zoledronic acid 5 mg once yearly
 
0.54 (0.32–0.92), P = 0.02
 
0.73 (0.55–0.98), 
P = 0.03
 
P = NS
N/R
N/R
0.7%
3.6%, P , 0.001 versus placebo
N/R
N/R
N/R
N/R
Fracture Reduction evaluation of  
Denosumab in Osteoporosis every  
6 Months (FReeDOM)17
Placebo
Denosumab 60 mg/3 months
 
0.32 (0.26–0.41), P , 0.001
 
0.80 (0.67–0.95), 
P = 0.01
 
0.60 (0.37–0.97), P = 0.04
N/R
Change versus placebo 
9.2%, P , 0.001 versus placebo
N/R
N/R
N/R
Change versus placebo 
-72%
N/R
N/R
Spinal Osteoporosis Therapeutic  
intervention (SOTi)15
Placebo
Strontium ranelate 2 g/day
 
0.59 (0.48–0.73), P , 0.001
 
P = NS
 
N/R
N/R
Change versus placebo 
14.4%, P , 0.001 versus placebo
N/R
Change versus placebo 
8.3%, P , 0.001 versus placebo
∼520 pmol/L‡
∼290 pmol/L‡
∼1.4 ng/mL‡
∼2.35 ng/mL‡
Treatment of Peripheral 
Osteoporosis (TROPOS)c 16
Placebo
Strontium ranelate 2 g/day
 
0.61 (0.51–0.73), P , 0.001
 
0.84 (0.702–0.995), 
P = 0.04
 
P = NS
N/R
N/R
N/R
Change versus placebo 
8.2%, P , 0.001 versus placebo
N/R
N/R
N/R
N/R
Notes: All trials were 3-year, randomized, double-blind, placebo-controlled with the exception of: aMean treatment duration was 4.2 years; b1-year trial; c5-year trial; 
*Risedronate 2.5 mg and 5 mg doses were combined for analysis of efficacy; †estimated from Figure1 from Liberman UA, et al. (1995) N Engl J Med. 333:1437–1443; ‡estimated 
from Figure 4 from Meunier PJ, et al (2004). N Engl J Med. 350:459–468.
Abbreviations: CI, confidence interval; N/R, not reported; RR, risk reduction; NS, not significant; BMD, bone mineral density; CTX, serum C-telopeptide of type I collagen; 
ALP, alkaline phosphatase.
  discontinuation of treatment resulted in a gradual reduction 
in BMD over 18 months, which did not fall below baseline 
(Figure 1D).51 This was associated with a sustained reduction 
in vertebral fracture risk over 18 months of follow-up.
In the Parathyroid Hormone and Alendronate (PaTH) 
study, postmenopausal women with osteoporosis were 
  randomized to receive treatment with PTH (1–84) for 
1 year followed by placebo for 1 year, PTH (1–84) and 
alendronate for 1 year followed by alendronate for 1 year 
or alendronate for 2 years. During the year of treatment 
with placebo that followed 1 year of treatment with PTH 
(1–84), BMD at the lumbar spine declined but did not 
Table 3 Summary of patient populations and treatments examined in trials of anabolic osteoporosis treatments
Study Patients Number of 
patients
Treatments
Active Comparative
Fracture Prevention Trial (FPT)14 PM women with $1 moderate or $2 mild  
vertebral fractures
1637 Teriparatide 20 μg 
Teriparatide 40 μg
Placebo
Treatment of Osteoporosis with 
Parathyroid Hormone Study (TOPS)71
PM women 45–54 years with lumbar spine,  
femoral neck or total hip BMD T score #-3.0 or  
BMD T score = -2.5 and 1–4 vertebral fractures 
PM women aged $55 years with BMD  
T score #-2.5 or BMD T score #-2.0  
and 1–4 vertebral fractures
2532 PTH (1–84)  
100 μg/day
Placebo
Note: All trials were 18-month, randomized, double-blind, placebo-controlled.
Abbreviations: PM, postmenopausal; BMD, bone mineral density; PTH, parathyroid hormone.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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return to baseline levels. Femoral neck BMD increased 
and total hip BMD did not change during the same period. 
Both P1NP and serum CTX decreased during the year of 
treatment with placebo with levels of P1NP returning to 
baseline at the end of 12 months and levels of serum CTX 
returning close to baseline. The proportion of fractures 
did not differ between any of the treatment groups over 
the 2-year period of the study.52
Osteoporosis treatments in clinical  
trials: summary
Clinical studies of different classes of osteoporosis treatments 
show that whilst all approved treatments increase bone den-
sity and provide a degree of fracture protection, the effects 
of discontinuing treatment differ both between classes and 
within them. The consequences of discontinuing treatment 
with estrogen or raloxifene are a rapid loss of BMD and an 
increase in BTMs. Despite this, there is some evidence that 
for healthy postmenopausal women who received treatment 
with HRT during their early postmenopausal years, a degree 
of vertebral fracture protection remained for a number of 
years after treatment was stopped.
For bisphosphonates, studies have shown that the 
antifracture efficacy may continue even when treatment 
is discontinued. This could be explained by the fact that 
bisphosphonates bind tightly to bone and once bound are 
released slowly during the process of bone turnover,53 
potentially making the bisphosphonate continuously avail-
able for some time after the patient has stopped taking the 
treatment. Overall, even when treatment for 3 years with 
alendronate and risedronate is discontinued, some anti-
fracture efficacy remains. Decreases in BMD were gradual 
and did not return to baseline within 1 year of discontinu-
ing risedronate treatment46 and 3 years of discontinuing 
  alendronate.44 Changes in BTM upon discontinuation of 
treatment do differ between alendronate and risedronate. For 
both drugs, BTMs increased after discontinuation; however, 
the degree of increase and the timeframe over which the 
increase occurs differ between the two drugs.44,46 The clini-
cal significance of these differences is currently unknown. 
What is also unclear from the available discontinuation 
data is which patients are likely to achieve the most com-
prehensive antifracture efficacy from continued treatment. 
Subgroup analysis of the FLEX study indicates that it is 
patients who remain at high risk for fracture after 5 years 
of treatment who benefit from continuing with treatment; 
however, numbers of fractures in this study were small and 
so the results should be interpreted with caution.44 Analysis 
T
a
b
l
e
 
4
 
S
u
m
m
a
r
y
 
o
f
 
r
e
s
u
l
t
s
 
f
r
o
m
 
t
r
i
a
l
s
 
o
f
 
a
n
a
b
o
l
i
c
 
o
s
t
e
o
p
o
r
o
s
i
s
 
t
r
e
a
t
m
e
n
t
s
S
t
u
d
y
T
r
e
a
t
m
e
n
t
s
F
r
a
c
t
u
r
e
 
r
e
d
u
c
t
i
o
n
 
v
e
r
s
u
s
 
p
l
a
c
e
b
o
 
o
v
e
r
 
1
8
 
m
o
n
t
h
s
 
(
R
R
 
[
9
5
%
 
C
I
]
)
C
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
o
v
e
r
 
 
1
8
 
m
o
n
t
h
s
 
(
p
e
r
c
e
n
t
a
g
e
)
V
e
r
t
e
b
r
a
l
N
o
n
v
e
r
t
e
b
r
a
l
H
i
p
L
u
m
b
a
r
 
s
p
i
n
e
 
B
M
D
F
e
m
o
r
a
l
 
n
e
c
k
 
B
M
D
S
e
r
u
m
 
C
T
X
S
e
r
u
m
 
P
1
N
P
F
r
a
c
t
u
r
e
 
P
r
e
v
e
n
t
i
o
n
 
T
r
i
a
l
 
(
F
P
T
)
1
4
P
l
a
c
e
b
o
T
e
r
i
p
a
r
a
t
i
d
e
 
2
0
 
μ
g
 
 
T
e
r
i
p
a
r
a
t
i
d
e
 
4
0
 
μ
g
 
0
.
3
5
 
(
0
.
2
2
–
0
.
5
5
)
,
 
P
 
#
 
0
.
0
0
1
0
.
3
1
 
(
0
.
1
9
–
0
.
5
0
)
,
 
P
 
#
 
0
.
0
0
1
 
0
.
4
7
 
(
0
.
2
5
–
0
.
8
8
)
 
0
.
4
6
 
(
0
.
2
5
–
0
.
8
6
)
 
N
/
R
 
N
/
R
1
.
1
%
9
.
7
%
,
 
P
 
,
 
0
.
0
0
1
 
v
e
r
s
u
s
 
p
l
a
c
e
b
o
1
3
.
7
%
,
 
P
 
,
 
0
.
0
0
1
 
v
e
r
s
u
s
 
p
l
a
c
e
b
o
-
0
.
7
%
2
.
8
%
,
 
P
 
,
 
0
.
0
0
1
 
v
e
r
s
u
s
 
p
l
a
c
e
b
o
5
.
1
%
,
 
P
 
,
 
0
.
0
0
1
 
v
e
r
s
u
s
 
p
l
a
c
e
b
o
N
/
R
N
/
R
 
N
/
R
N
/
R
N
/
R
 
N
/
R
T
r
e
a
t
m
e
n
t
 
o
f
 
O
s
t
e
o
p
o
r
o
s
i
s
 
w
i
t
h
 
P
a
r
a
t
h
y
r
o
i
d
 
H
o
r
m
o
n
e
 
S
t
u
d
y
 
(
T
O
P
S
)
7
1
P
l
a
c
e
b
o
P
T
H
 
(
1
–
8
4
)
 
 
1
0
0
 
μ
g
/
d
a
y
 
0
.
4
2
 
(
0
.
2
4
–
0
.
7
2
)
,
 
P
 
=
 
0
.
0
0
1
 
P
 
=
 
N
S
 
N
/
R
-
0
.
3
2
3
%
6
.
5
3
%
,
 
P
 
,
 
0
.
0
0
1
 
v
e
r
s
u
s
 
p
l
a
c
e
b
o
-
0
.
6
9
1
.
7
8
,
 
P
 
,
 
0
.
0
0
1
 
v
e
r
s
u
s
 
p
l
a
c
e
b
o
N
/
R
U
r
i
n
a
r
y
 
N
T
X
 
8
5
%
N
/
R
8
0
%
N
o
t
e
:
 
A
l
l
 
t
r
i
a
l
s
 
w
e
r
e
 
1
8
-
m
o
n
t
h
,
 
r
a
n
d
o
m
i
z
e
d
,
 
d
o
u
b
l
e
-
b
l
i
n
d
,
 
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
.
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
C
I
,
 
c
o
n
fi
d
e
n
c
e
 
i
n
t
e
r
v
a
l
;
 
N
/
R
,
 
n
o
t
 
r
e
p
o
r
t
e
d
;
 
R
R
,
 
r
i
s
k
 
r
e
d
u
c
t
i
o
n
;
 
B
M
D
,
 
b
o
n
e
 
m
i
n
e
r
a
l
 
d
e
n
s
i
t
y
.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
193
Consequences of nonadherence to osteoporosis therapy
Figure 1 Changes in lumbar spine BMD: A) during, and after treatment with raloxifene (mean ± SeM [g/cm2]);43 B) during alendronate treatment in the FiT trial and 
alendronate or placebo treatment in the FLeX trial (mean percent change from baseline);44 C) during 3 years of blinded treatment with placebo or risedronate 5 mg daily, 
followed by 1 year of open label treatment with calcium (and vitamin D, if needed) [mean percent change from baseline];46 D) during and after treatment with teriparatide in 
women who did not use any osteoporosis drugs during the 18 month follow-up period (mean percent change from baseline).51
Notes: A) *P , 0.05 for within-group analysis (baseline versus. treatment); †P , 0.05 for within-group analysis (treatment versus. post-treatment); B) BMD = bone mineral 
density, FiT = Fracture intervention Trial, FLeX = Fracture Intervention Trial Long-term Extension. Error bars indicate 95% confidence intervals. Data are shown for the 
period spanning the beginning of FiT through the completion of FLeX, a total of 10 years; C) *P , 0.05 from baseline based upon a paired t-test; #P , 0.05 from placebo;   
D) eP = end point of the Fracture prevention Trial (end of teriparatide treatment), *P , 0.001.
L
u
m
b
a
r
 
s
p
i
n
e
 
B
M
D
 
C
h
a
n
g
e
f
r
o
m
 
F
I
T
 
b
a
s
e
l
i
n
e
,
 
m
e
a
n
,
 
%
 
-2
0
2
4
6
8
10
12
14
16
Year Year
5
FLEX FIT
Lumbar Spine
Years
0
1
2
3
4
5
6
*#
*# *# *#
*#
*#
*#
* * * * *
*
*
RIS 5 mg Placebo
FLEX Treatment Group: Alendronate (Pooled) Pacebo
Years
0.80
0.85
0.90
0.95
1.00
1.05
1.15
M
e
a
n
 
L
u
m
b
a
r
 
S
p
i
n
e
 
B
M
D
V
a
l
u
e
s
 
(
g
r
/
c
m
2
)
 
w
i
t
h
 
S
E
M
†
*
*
On treatmentO ff treatment
1.10
†
o b e c a l P E E CR AL 60
L
u
m
b
a
r
 
s
p
i
n
e
 
B
M
D
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
,
 
%
A B
CD
L
u
m
b
a
r
 
s
p
i
n
e
 
B
M
D
 
%
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
(n = 209, 211, 193)
(n = 233, 235, 216)
(n = 190, 186, 171)
EP
10
5
0
15
20
EP + 6 mo EP + 18 mo
*
*
*
*
*
*
40-µg teriparatide group 20-µg teriparatide group Placebo
On treatment Off treatment On treatment Off treatment
0 0
01 234
56 1 234 01234
of data from the HORIZON-PFT extension study will be 
required to determine if a similar pattern exists following 
treatment with zoledronic acid.
Data on the effects of discontinuing treatment with 
RANKL inhibitors are limited. A phase III study of deno-
sumab showed that when treatment was halted there was a 
rapid decrease in lumbar spine and total hip BMD back to 
baseline within 12 months48 and a phase II study showed an 
increase in BTMs to beyond baseline levels within the same 
period.49 There are currently no data on whether antifrac-
ture efficacy continues when patients stop treatment with 
denosumab.
When treatment with strontium ranelate is stopped, 
BMD decreases and BTMs increase although within the 
first 12 months after treatment is halted, there is no reduc-
tion in antifracture efficacy.50 Halting treatment with PTH 
results in a gradual decline in BMD but without a loss in 
vertebral fracture risk reduction during the first 18 months 
after   discontinuing treatment.51
Drug holidays
The issue of whether physicians should consider a drug holiday 
for patients taking osteoporosis treatments is closely related to 
the consequences of discontinuing versus continuing treatment 
over the long term. The FLEX study, as previously discussed, 
showed that an additional 5 years of alendronate treatment fol-
lowing an initial 5 years did not significantly reduce the risk of 
morphometric vertebral fractures or nonvertebral fractures in 
the overall population.44 However, in women with low femoral 
neck BMD, there was a significant reduction in risk of nonverte-
bral fractures with continued treatment.45 In addition, the results 
from the follow-up to the VERT studies of risedronate showed 
that fracture risk remained reduced 1 year after treatment was 
discontinued.46 These data suggest that patients may be able 
to take a break from treatment without incurring additional 
fracture risk. However, the post-hoc analysis of women with 
low femoral neck BMD in the FLEX study suggest that patients 
who may be considered to still be at high risk for fracture after 
5 years of treatment should continue with treatment.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Figure 2 Changes in femoral neck BMD: A) during and after treatment with raloxifene (mean ± SeM [g/cm2]);43 B) during alendronate treatment in the FiT trial and 
alendronate or placebo treatment in the FLeX trial (mean percent change from baseline);44 C) during 3 years of blinded treatment with placebo or risedronate 5 mg daily, 
followed by 1 year of open label treatment with calcium (and vitamin D, if needed) [mean percent change from baseline].46
Notes: A) *P , 0.05 for within-group analysis (baseline versus treatment); †P , 0.05 for within-group analysis (treatment versus post-treatment); B) BMD = bone mineral 
density, FiT = Fracture intervention Trial, FLeX = Fracture Intervention Trial Long-term Extension. Error bars indicate 95% confidence intervals. Data are shown for the 
period spanning the beginning of FiT through the completion of FLeX, a total of 10 years; C) *P , 0.05 from baseline based upon a paired t-test’ #P , 0.05 from placebo.
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The issue of which patients may be suitable for a drug 
holiday, and the length of that holiday, is one that requires 
substantially more research on the long-term benefits versus 
the risks of specific treatments from well-designed, placebo-
controlled trials. It is likely that only certain subgroups of low 
risk patients should be considered for a break in treatment 
with patients at high risk remaining on treatment.
Drug holidays also need to be carefully considered in light 
of the issues of poor treatment adherence. If patients have 
not adhered to treatment, then the expected gains in BMD, 
decreased bone turnover and ultimately, protection from 
fracture, are unlikely to exist. Therefore, when a patient is 
assessed after several years of treatment, the assumption that 
they have received the equivalent benefit to that observed by 
patients participating in clinical trials may be false. Given 
that studies have shown that physicians can overestimate the 
adherence of their patients, reassessment of the patient’s risk 
factors for fracture is critical to ensure that discontinuing 
treatment is the appropriate course of action for a specific 
patient. Ongoing reassessment of patients who stop treatment 
should also be considered.
Discussion
Osteoporosis and the fragility fractures associated with the 
disease are an increasing problem and pose an ever-growing 
burden to a society with an increasing elderly population. 
However, there are still a number of barriers to achieving 
effective fracture protection for patients, despite the availabil-
ity of a wide range of efficacious treatments. These include 
obtaining a diagnosis, being prescribed an efficacious treat-
ment and compliance with the treatment regimen.
Optimum fracture protection for patients with osteoporosis 
requires that they adhere to treatment. Despite this, numerous 
papers report that many patients do not continue with treat-
ment after diagnosis.24,25,27,29–31,54 Factors affecting adherence 
include a) a belief in the importance of taking medication 
for osteoporosis,30 b) beliefs regarding medications and 
health in general,55,56 c) doctor and other healthcare provider Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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relationships38,55 and d) information exchange between 
healthcare professionals and patients.38 A wide variety of 
interventions have been studied to improve adherence. These 
include: monitoring a patient’s BTMs and providing feedback 
to them based on their response to therapy, structured patient 
education presented face-to-face or via brochures, letters, 
or telephone calls, telephone patient counseling in order to 
address individual barriers to medication adherence and use 
of a weekly dose versus a monthly dose together with a patient 
support program.57 The authors of a systematic review of such 
interventions concluded that one-dimensional strategies for 
improving adherence were ineffective and that, as with other 
chronic long-term diseases, the most effective strategies were 
likely to be multifaceted.57 Results from several studies and 
a recent meta-analysis suggest that osteoporosis therapy also 
reduces mortality risk in women and possibly men.58–61 This 
reported mortality benefit should have an impact on the way 
osteoporosis treatment is viewed and used, and should help 
to encourage patients to be more compliant.
If clinicians are aware that even with interventions to 
improve adherence to treatment, some patients will still 
continue to be nonadherent, it is important that they know 
what happens when treatment is discontinued. Differences 
in the design of follow-up or discontinuation studies of indi-
vidual osteoporosis treatments mean that it is not possible 
to make direct comparisons between different treatments. 
Although all the treatments discussed have shown BMD 
declining once treatment is discontinued, the rate of loss 
of bone density differs according to treatment. Markers of 
bone turnover have also increased once treatment has been 
discontinued; however, the rate at which BTMs rise also 
differs between treatments. Examination of the reduction in 
fracture risk in patients once they have stopped treatments 
such as alendronate, risedronate or strontium indicates that 
some degree of fracture risk reduction may remain; although 
these data are mostly uncontrolled and therefore must be 
interpreted with caution. Patients in these studies were taking 
active treatment for between 3 and 5 years prior to treatment 
Figure 3 Changes in bone resorption markers: A) serum β-CTX during alendronate treatment in the FiT trial and alendronate or placebo treatment in the FLeX trial 
(mean);44 B) urinary NTX during 3 years of blinded treatment with placebo or risedronate 5 mg daily, followed by 1 year of open label treatment with calcium (and vitamin 
D, if needed) [median percent change from baseline];46 C) serum β-CTX during and after treatment with denosumab (median value, ng/mL).49
Notes: A) FiT = Fracture intervention Trial, FLeX = Fracture Intervention Trial Long-term Extension. Error bars indicate 95% confidence intervals. Data are shown for the 
period spanning the beginning of FiT through the completion of FLeX, a total of 10 years; B) *P , 0.05 from baseline based upon a Signed Rank t-test, #P , 0.05 from placebo; 
C) Group receiving 30 mg Q3M discontinued denosumab treatment at Month 24 and were retreated with 60 mg Q6M denosumab at Month 36. Groups receiving 210 mg 
Q6M or alendronate discontinued treatment for the last 24 months. The dashed line at Month 24 indicates the time at which dosing was reallocated.
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being stopped and it is therefore likely that these patients 
had achieved and were maintaining the maximum fracture 
protection from each of the respective treatments when it was 
halted. This level of fracture protection may not be achieved 
in patients in the real-world as adherence studies indicate 
that a large number of patients discontinue treatment within 
the first 6 months. It is also important to examine which 
patient subgroups maintained their fracture protection once 
treatment had been   discontinued. This is highlighted by the 
results from the FLEX trial of alendronate which showed 
that only patients with a low femoral neck BMD T-score after 
5 years of alendronate treatment continued to benefit from an 
additional 5 years of treatment. The lack of increased efficacy 
and the potential safety concerns associated with long-term 
treatment have led to questions regarding whether clinicians 
should instigate a drug holiday for patients who have taken 
osteoporosis treatments, specifically bisphosphonates for 
5 years or more. Although data on this topic are limited, it may 
be appropriate for patients who continue to be at high risk for 
fracture to remain on treatment and patients at low risk for 
fracture to cease treatment and continue to be monitored.
Overall, the consequences of not being treated or not 
adhering to treatment are high for patients with   osteoporosis. 
Without effective treatment and adherence to treatment, 
patients will continue to be at high risk for fracture and the 
associated morbidity and mortality. Clinicians must ensure 
that their patients understand the significance of the disease, 
the importance of their treatment and are able to discuss with 
them any issues they face whilst taking a specific treatment.
Conclusion
Patients who are not diagnosed or followed-up after a fragility 
fracture are at high risk of experiencing another fracture in the 
future. Once diagnosed, patients who fail to comply with treat-
ment for osteoporosis are known to increase their risk of future 
fracture regardless of the efficacy of the treatment prescribed.62 
Despite the availability of a range of efficacious treatments, a 
lack of adherence is a well recognized issue. Failure to tackle 
this has consequences both for the patient, in terms of avoid-
able morbidity and mortality, and for healthcare providers who 
are required to invest more time and fund additional treatment. 
Given that osteoporosis is an ever-growing burden, improv-
ing adherence to treatment will require clinicians to develop 
multifactorial approaches to adherence and to tackle issues 
specific to individual patients. Additional data are required 
on the long-term changes in fracture risk when treatments are 
discontinued to help clinicians determine how to provide their 
patients with optimum protection from fracture.
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